日本在线观看不卡,国产成人免费观看,国产gaysex男同视频chinese,欧美一级www

樹(shù)人論文網(wǎng)一個(gè)專(zhuān)業(yè)的學(xué)術(shù)咨詢(xún)網(wǎng)站?。?!
樹(shù)人論文網(wǎng)
學(xué)術(shù)咨詢(xún)服務(wù)

Expert Opinion On Drug Safety

來(lái)源: 樹(shù)人論文網(wǎng) 瀏覽次數(shù):1213次
Bimonthly
創(chuàng)刊時(shí)間:2002
所屬分區(qū):3區(qū)
周期:Bimonthly
ISSN:1474-0338
影響因子:3.22
是否開(kāi)源:No
年文章量:134
錄用比:較易
學(xué)科方向:藥學(xué)
研究方向:醫(yī)學(xué)
通訊地址:INFORMA HEALTHCARE, TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON, ENGLAND, EC2A 4LQ
官網(wǎng)地址:http://www.tandfonline.com/loi/ieds20#.V48bfkz9cSQ
投稿地址:https://mc.manuscriptcentral.com/eods
網(wǎng)友分享經(jīng)驗(yàn):較慢,6-12周

Expert Opinion On Drug Safety雜志中文介紹

Published by Informa Pharmaceutical Science (formerly Ashley Publications). ISSN: 1474-0338.Expert Opinion on Drug Safety (EODS) is a new bimonthly journal providing comprehensive coverage of the safety of new and established drug therapies. With the ever-expanding armamentarium of drugs and drug therapies available, rational pharmacotherapy today is a complex art. At the forefront of this problem is the need to provide the most effective drug regimen whilst avoiding any adverse drug reactions. From the first point of concept to establishment on the market, monitoring the safety of a drug is critical to a drug's development and commercialisation. With pharmaceutical pipelines burgeoning and further growth of medicines likely in the post-genomic era, there is rapid expansion in the quantity of primary data relating to drug safety. Through systematic review and evaluation, Expert Opinion on Drug Safety seeks to unravel this vast amount of information and provide clear and informed guides to this increasingly important area.

Expert Opinion On Drug Safety雜志英文介紹

由Informa Pharmaceutical Science出版(原Ashley Publications)。ISSN: 1474 - 0338。《藥物安全專(zhuān)家意見(jiàn)》(EODS)是一份新出版的雙月刊,全面報(bào)道新藥物和現(xiàn)有藥物治療的安全性。隨著藥物和藥物治療手段的不斷發(fā)展,今天的合理藥物治療是一門(mén)復(fù)雜的藝術(shù)。這個(gè)問(wèn)題的首要問(wèn)題是需要提供最有效的藥物治療方案,同時(shí)避免任何藥物不良反應(yīng)。從概念的第一點(diǎn)到市場(chǎng)的建立,監(jiān)測(cè)藥物的安全性對(duì)藥物的開(kāi)發(fā)和商業(yè)化至關(guān)重要。在后基因組時(shí)代,隨著藥物管道的蓬勃發(fā)展和藥物的進(jìn)一步發(fā)展,與藥物安全性有關(guān)的原始數(shù)據(jù)量迅速增加。通過(guò)系統(tǒng)的審查和評(píng)估,藥品安全專(zhuān)家意見(jiàn)力求揭示這一龐大的信息,并為這一日益重要的領(lǐng)域提供明確和知情的指導(dǎo)。

Expert Opinion On Drug Safety期刊H指數(shù)

影響因子 h-index Gold OA文章占比 研究類(lèi)文章占比 OA開(kāi)放訪(fǎng)問(wèn) 平均審稿速度
4.011 62 8.90% 41.25% 未開(kāi)放 較慢,6-12周

Expert Opinion On Drug Safety期刊JCR分區(qū)趨勢(shì)圖

Expert Opinion On Drug Safety影響因子